Collagenase Clostridium Histolyticum (Xiaflex) — CPB 1061 | AETNA Coverage Update

Aetna modified CPB 1061 covering collagenase clostridium histolyticum (Xiaflex), effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its Xiaflex coverage policy under CPB 1061 in the Aetna collagenase clostridium histolyticum coverage policy. This change affects claims billed with HCPCS J0775 (collagenase clostridium histolyticum, 0.01 mg), alongside CPT 20550 and 96372, for covered diagnoses including Dupuytren's contracture (M72.0) and Peyronie's disease (N48.6). If your team bills Xiaflex for commercial plan members, review your charge capture and documentation requirements before September 26, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Collagenase Clostridium Histolyticum (Xiaflex) — CPB 1061
Policy Code	CPB 1061
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	Medium
Specialties Affected	Orthopedic surgery, urology, hand surgery, plastic surgery
Key Action	Audit active Xiaflex claims and verify diagnosis codes against M72.0 and N48.6 before billing with J0775

---

Aetna Xiaflex Coverage Criteria and Medical Necessity Requirements 2025

The core of this policy update is medical necessity. Aetna covers collagenase clostridium histolyticum billing under CPB 1061 Aetna system for two primary diagnoses: palmar fascial fibromatosis (Dupuytren's contracture, M72.0) and induration of penis plastica (Peyronie's disease, N48.6).

These are not soft indications. Aetna's coverage policy is built around specific clinical diagnoses — not symptoms, not suspected conditions. Your documentation needs to lock in the correct ICD-10 code before the claim goes out.

For Dupuytren's contracture, the covered procedure pathway runs through CPT 20550 (injection into tendon sheath, ligament, or aponeurosis) paired with J0775. For Peyronie's disease, the injection route typically aligns with CPT 96372 (therapeutic subcutaneous or intramuscular injection). Make sure your charge capture matches the clinical route of administration — mismatches between the injection CPT and the diagnosis are a fast track to a claim denial.

Prior authorization is the variable your team needs to confirm before every Xiaflex encounter. Aetna's commercial plans vary in their prior auth requirements by plan type and region. Don't assume a prior auth from six months ago covers a new treatment cycle. Verify current requirements against the active member's plan before scheduling.

The medical necessity threshold for reimbursement under this policy is tied directly to the diagnosis. Billing J0775 without a supported ICD-10 — one of the covered codes listed in this policy — will result in a denial. That's not a gray area. It's a hard stop in Aetna's adjudication logic.

---

Aetna Xiaflex Exclusions and Non-Covered Indications

The ICD-10 codes in this policy tell you as much about what Aetna won't cover as what they will. The F52.x range (F52.0 through F52.9) and F66 appear in the policy's code set. These codes cover sexual dysfunction not due to a substance or known physiological condition, and other sexual disorders.

The presence of these codes in the policy alongside the covered indications is a flag for your billing team. These diagnoses are listed — but they are not in the covered group. J0775 billed against F52.x or F66 does not meet Aetna's medical necessity criteria under CPB 1061.

The real issue here is documentation discipline. If a provider documents Peyronie's disease (N48.6) and a coder defaults to an F52.x code because of how the encounter is described, that claim denies. Train your coders to distinguish between N48.6 (the structural/physical diagnosis that's covered) and the F52 range (psychological sexual dysfunction that's not covered under this policy).

This is not a gray zone where you appeal and win. Aetna's coverage policy is explicit about which indications support medical necessity for Xiaflex. If the diagnosis doesn't match M72.0 or N48.6, the claim doesn't have legs.

---

Coverage Indications at a Glance

---

Aetna Xiaflex Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Collagenase Clostridium Histolyticum Under CPB 1061

HCPCS Codes Covered When Selection Criteria Are Met

Code	Type	Description Copy
J0775	HCPCS	Injection, collagenase clostridium histolyticum, 0.01 mg (not for cosmetic use)

Other CPT Codes Related to CPB 1061

These codes appear in the policy as related billing codes. They are the injection procedure codes paired with J0775 for the drug itself.

Code	Type	Description Copy
20550	CPT	Injection(s); single tendon sheath, or ligament, aponeurosis (e.g., plantar "fascia")
96372	CPT	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

Key ICD-10-CM Diagnosis Codes Under CPB 1061

---

A Word on Xiaflex Reimbursement and Claim Risk

Xiaflex is an expensive drug. J0775 is billed per 0.01 mg — and a full treatment cycle for Dupuytren's or Peyronie's involves multiple injections. The reimbursement exposure on a denied Xiaflex claim is not trivial.

That's exactly why the F52.x coding risk is worth taking seriously. A single miscoded encounter can generate a denial worth several thousand dollars in drug cost alone. Appeals are possible, but they're slow and not guaranteed when the diagnosis code is genuinely wrong.

The billing guidelines here are straightforward. Two covered diagnoses. One drug code. Two injection CPT codes. The complexity isn't in the code set — it's in making sure documentation, diagnosis coding, and prior auth all line up before the claim goes out. Build that workflow now, before the September 26, 2025 effective date.

---